Notes to Consolidated Financial Statements
Three Months Ended December 31, 2017 and 2016
(Unaudited and Unreviewed)
1.
ORGANIZATION
Enerkon Solar International, Inc. (“ENKS”) is a holding company which was incorporated in Nevada on June 13, 1986. The name of the Company was changed from Castle Holding Corp. (“CHOD”) to ENKS on November 2, 2017. The subsidiaries of ENKS are as follows:
|
1.
|
Castle Royalties Corp. (incorporated in New York April 11, 1991) – name changed from Church Street Securities Corp. on March 16, 2015; assignee of License Agreement with Emergent Health Corporation effective March 16, 2015 (see Note 5).
|
|
|
|
|
2.
|
SAS Health and Beauty Corp. (incorporated in New York May 27, 1994) – name changed from Wall Street Indians, Ltd. on March 31, 2015; manufactures and markets a skin care product (commencing July 2015) and vitamin supplements (commencing November 2016).
|
|
|
|
|
3.
|
The Unlisted Stock Market Corporation (incorporated in New York December 9, 1999) – no operations from inception.
|
|
|
|
|
4.
|
Shark Venture Capital Inc. (incorporated in Nevada December 22, 2014) – plans to engage in venture capital activities.
|
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Interim financial statements – The accompanying unaudited interim financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all information and footnotes required by generally accepted accounting principles for annual audited financial statements. In the opinion of management, the unaudited financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments considered necessary for a fair presentation.
The results of operations for the three months ended December 31, 2017 are not necessarily indicative of the results to be expected for the year ending September 30, 2018. The accompanying unaudited interim financial statements should be read in conjunction with the Company’s financial statements and notes related thereto for the years ended September 30, 2017 and 2016 included in our Form 10-K filed with the SEC.
Principles of consolidation – The consolidated financial statements include the accounts of ENKS and its subsidiaries (collectively, the “Company”). All significant intercompany balances and transactions have been eliminated in consolidation.
Use of estimates – The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Cash and cash equivalents - The Company considers highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.
ENERKON SOLAR INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
Three Months Ended December 31, 2017 and 2016
(Unaudited and Unreviewed)
Marketable securities - Marketable securities consist of trading securities valued at market. All fair value measurements are based on Level 1 inputs (i.e., closing trading prices of respective marketable securities). Unrealized gains and losses are reflected in income ($17,000 and ($38,162) for the three months ended December 31, 2017 and 2016, respectively).
Inventory – Inventory is stated at the lower of cost (first–in, first–out method) or market (net realizable value). At December 31, 2017 and September 30, 2017, substantially all inventory are finished goods available for sale.
Revenue recognition – Revenues are recognized upon delivery of the products, at which time title passes to the customer, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an arrangement exists; the sales price is fixed or determinable; and collectibility is deemed probable.
Income taxes – Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.
Net income (loss) per common share – Basic net income (loss) per common share is calculated based upon the weighted average number of common shares outstanding. Diluted net income (loss) per common share is calculated based upon the weighted average number of common shares outstanding and dilutive convertible preferred shares outstanding.
Recent accounting pronouncements – Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations from adoption of these standards is not expected to be material.
3. MARKETABLE SECURITIES, AT MARKET VALUE
At December 31, 2017 and September 30, 2017, marketable securities consist of:
|
|
December 31,
2017
|
|
|
September 30,
2017
|
|
|
|
|
|
|
|
|
1,000,000 and 1,000,000 shares, respectively, Gold Mining USA Inc. (GMUI)
|
|
$
|
22,000
|
|
|
$
|
5,000
|
|
Various
|
|
|
100
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
22,100
|
|
|
$
|
5,100
|
|
ENERKON SOLAR INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
Three Months Ended December 31, 2017 and 2016
(Unaudited and Unreviewed)
4. INVESTMENT IN EMERGENT HEALTH CORPORATION COMMON STOCK
On November 20. 2014, pursuant to a Stock Purchase Agreement involving a change in control of ENKS, ENKS acquired 2,000,000 restricted shares of Emergent Health Corporation (“EMGE”) common stock in exchange for the issuance of 2,000,000 restricted shares of ENKS common stock. The EMGE investment was initially valued at an estimated fair value of $250,000. The closing trading price of EMGE free trading common stock at November 20, 2014 was $0.49 per share.
At September 30, 2015, the Company recognized an impairment loss on the investment in EMGE common stock of $90,000 and reduced the carrying value from $250,000 to $160,000. At December 31, 2015, the Company recognized an additional impairment loss on the investment in EMGE common stock of $40,000 and reduced the carrying value from $160,000 to $120,000. At March 31, 2016, the Company recognized an additional impairment loss on the investment in EMGE common stock of $40,000 and reduced the carrying value from $120,000 to $80,000. At September 30, 2016, the Company recognized an additional impairment loss on the investment in EMGE common stock of $20,000 and reduced the carrying value from $80,000 to $60,000. At March 31, 2017, the Company recognized an additional impairment loss on the investment in EMGE common stock of $20,000 and reduced the carrying value from $60,000 to $40,000. At September 30, 2017, the Company recognized an additional impairment loss on the investment in EMGE common stock of $20,000 and reduced the carrying value from $40,000 to $20,000. The closing trading price of EMGE free trading common stock at September 30, 2017 and December 31, 2017 was $0.0156 per share and $0.01 per share, respectively.
5. LICENSE AGREEMENT WITH EMERGENT HEALTH CORPORATION
On November 20, 2014, pursuant to the Stock Purchase Agreement involving a change in control of ENKS, ENKS was assigned effective January 1, 2015 the License Agreement between Cappello’s, Inc, (Licensor) and EMGE (Licensee) dated August 26, 2014 (the “EMGE License Agreement”) in exchange for the issuance of 2,000,000 restricted shares of ENKS common stock. The EMGE License Agreement was valued at its estimated fair value of $30,000 based upon 2014 royalties.
The EMGE License Agreement provided for Licensee’s payment of quarterly royalty payments to Licensor equal to 5% of the first $1,000,000 of annual net sales of the Licensed Products, 4% of the next $1,000,000 of annual net sales, 3% of the next $1,000,000 of annual net sales, 2% of the next $2,000,000 of annual net sales, and 1% of all additional annual net sales. The term of the EMGE License Agreement was to upon the expiration of the last to expire of the Patent Rights. In the event the Base Sales of any one or more of the Licensed Products did not increase by 15% per year over each prior calendar year (“Underperforming Licensed Products”) and the Licensee did not pay royalties based on 15% annual increases in Base Sales for the Underperforming Licensed Product(s), Licensor could terminate the license for such Underperforming Licensed Product(s) or convert the license from an exclusive license to a non-exclusive license for such Underperforming Licensed Product(s). During the term, Licensor was to keep Licensee informed of the progress of the Patent Rights in the U.S. Patent Office and was to direct and control all aspects of the prosecution and maintenance of the Patent Rights using patent counsel of its choice; Licensee was to pay all reasonable costs and fees attributable to the Patent Rights including patent maintenance fees, government fees and attorney fees.
ENERKON SOLAR INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
Three Months Ended December 31, 2017 and 2016
(Unaudited and Unreviewed)
Based on the calendar year 2015 sales of the licensed products reported to ENKS by EMGE, the Company was entitled to royalties of $18,528. However, the Company collected royalties of only $572 from EMGE in 2015. Due to the uncertainty of future collections from EMGE, the Company has not recognized the remaining $17,956 royalties due at December 31, 2015.
EMGE did not report sales of the Licensed Products to ENKS in the first quarter 2016 or the second quarter 2016 and did not remit any royalties to ENKS. On April 28, 2016, ENKS notified EMGE that the EMGE License Agreement was terminated.
In November 2016, the Company collected $1,500 of current royalties from EMGE. At September 30, 2017, the Company recognized an impairment loss on the license agreement with Emergent Health Corporation of $30,000 and reduced the carrying value from $30,000 to $0.
6. LOANS PAYABLE TO AFFILIATES
Loan payable to affiliates consist of:
|
|
December 31,
2017
|
|
|
September 30,
2017
|
|
|
|
|
|
|
|
|
SAS Health and Beauty Corp. Promissory
|
|
|
|
|
|
|
Note due John V. Cappello, chief executive
|
|
|
|
|
|
|
officer of the Company, non-interest
|
|
|
|
|
|
|
bearing, due December 1, 2016
|
|
$
|
15,000
|
|
|
$
|
15,000
|
|
|
|
|
|
|
|
|
|
|
Loans payable to entities affiliated with
|
|
|
|
|
|
|
|
|
president and former treasurer of the Company,
|
|
|
|
|
|
|
|
|
non-interest bearing, due on demand
|
|
|
80
|
|
|
|
3,081
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
15,080
|
|
|
$
|
18,081
|
|
7. STOCKHOLDERS’ EQUITY
Class A Convertible Preferred Stock
From March 2001 to September 2001, ENKS sold a total of 706,750 shares of Class A Convertible Preferred Stock for gross proceeds of $706,750.
Each share of Class A Convertible Preferred Stock is convertible at any time into one share of the Company’s Common Stock at the election of the Class A Convertible Preferred Stockholder. At any time, ENKS may require conversion of the Class A Convertible Preferred Shares provided that ENKS Common Stock closes at a price of $1.50 per share or higher for more than 20 consecutive business days. At any time after one year from the issue date of the Class A Convertible Preferred Shares, ENKS may require conversion of the Class A Convertible Preferred Shares provided that ENKS pay the Class A Convertible Preferred Stockholder $0.50 per Class A Convertible Preferred Share.
ENERKON SOLAR INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
Three Months Ended December 31, 2017 and 2016
(Unaudited and Unreviewed)
The Class A Convertible Preferred Shares are non-voting and have a first priority, up to $1.00 per Class A Convertible Preferred Share, in the event of liquidation of ENKS.
Class B Preferred Stock
Effective June 1, 2015, CHOD issued 100,000 shares of Class B Preferred Stock (valued at $10,000) to John V. Cappello, chief executive officer of the Company, in connection with a $15,000 loan made to SAS Health and Beauty Corp., subsidiary of ENKS (see Note 6). Each share of Class B Preferred Stock is entitled to 100 votes per share but has no conversion, liquidation, or dividend rights.
Common Stock
On January 6, 2017, the bylaws of the Company were amended by unanimous consent of two stockholders holding a majority of the voting rights of the Company’s stockholders. Among other things, the amended bylaws provide that the Company’s present chief executive officer John V. Cappello be permitted 10 votes on any matter presented to the Board of Directors and that Cappello is to hold this voting right in perpetuity and may pass this voting right on or relinquish it at his discretion in the future.
8. INCOME TAXES
ENKS files a consolidated income tax return with its subsidiaries for federal reporting purposes. ENKS and its subsidiaries file separate income tax returns for state reporting purposes.
The provisions for (benefit from) income taxes consisted of:
|
|
Three Months Ended
December 31,
|
|
|
|
2017
|
|
|
2016
|
|
Current:
|
|
|
|
|
|
|
Federal
|
|
$
|
-
|
|
|
$
|
-
|
|
State
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Deferred:
|
|
|
|
|
|
|
|
|
Federal
|
|
|
5,893
|
|
|
|
(13,236
|
)
|
State
|
|
|
1,205
|
|
|
|
(2,706
|
)
|
Change in valuation allowance
|
|
|
(7,098
|
)
|
|
|
15,942
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
$
|
-
|
|
|
$
|
-
|
|
ENERKON SOLAR INTERNATIONAL, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
Three Months Ended December 31, 2017 and 2016
(Unaudited and Unreviewed)
The Company’s effective tax rate differed from the United States Federal income tax rate for the following reasons:
|
|
Three Months Ended
December 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
|
|
|
|
|
Computed Federal income tax at 34%
|
|
$
|
6,303
|
|
|
$
|
(14,156
|
)
|
Computed state income tax, net of Federal tax effect
|
|
|
795
|
|
|
|
(1,786
|
)
|
Change in valuation allowance
|
|
|
(7,098
|
)
|
|
|
15,942
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
$
|
-
|
|
|
$
|
-
|
|
As a result of The Tax Cuts and Jobs Act (Tax Legislation) enacted on December 22, 2017, the United States corporation income tax rate is 21% effective January 1, 2018. Accordingly, we have reduced our deferred income tax asset relating to prior year net operating loss carryforwards and capital loss carryforwards (and the valuation allowance thereon) by $199,551 from $521,903 at September 30, 2017 to $322,352 at December 31, 2017.
Based on management's present assessment, the Company has not yet determined it to be more likely than not that a deferred tax asset of up to $322,352 attributable to the future utilization of $1,132,978 of prior year net operating loss carryforwards and $402,032 of capital loss carryforwards will be realized. Accordingly, the Company has maintained a 100% allowance against the deferred tax asset in the financial statements at September 30, 2017 and December 31, 2017. The Company will continue to review this valuation allowance and make adjustments as appropriate. The net operating loss carryforwards expire as follows: $170,363 in year 2021, $694,345 in year 2022, $135,943 in year 2023, $66,021 in year 2024, $39,208 in year 2025, and $27,098 in year 2036. The capital loss carryforward of $402,032 expires $49,175 in year 2018, $1,855 in year 2021, and $351,002 in year 2022.
Current United States income tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited.
9.
COMMITMENTS AND CONTINGENCIES
Since December 2005, the Company has been using space in Freeport New York provided by a public accounting firm owned by the Company’s former treasurer at no cost to the Company.
From September 2015 to August 2016, the Company also occupied office space in King of Prussia, Pennsylvania under a lease at a rent of $950 per month. Since September 2016, the Company has been using other space in King of Prussia, Pennsylvania provided by EMGE at no cost to the Company. Management of the Company is currently working with EMGE to revive its business model and become viable.
Effective November 7, 2017, the chief executive officer and controlling shareholder of the Company completed an Escrow Agreement with certain parties affiliated with an entity engaged in solar energy operations. Under the agreement, a change in control of the Company would occur. Closing of the transaction is subject to completion of certain conditions precedent to closing.